Summary
This is a substudy of the primary PRECISION-ITS study (ACTRN12624000079549), which will run at the same time.
This study involves developing and evaluating a pharmacogenomics education and implementation program for pharmacists in Australia.
Pharmacogenomics is the study of how a person's genetic makeup influences their response to medications. It combines aims to understand why individuals may respond differently to the same drug.
The program will be developed by a multidisciplinary working group that invovles healthcare professionals, consumers, and patients/carers with lived experience. Surveys assessing the knowledge attitudes, perceptions and acceptability of pharmacogenomics amongst consumers and healthcare professionals in the adult and paediatric oncology setting will be used to inform the program's design.
Who is it for?
You may be eligible to complete the survey(s) if you have received or cared for someone who has received treatment for cancer in Australia, are aged 15 years or above, or are a healthcare professional working in oncology within Australia.
Study details
The program will be delivered to pharmacists at sites participating in the primary study. You may be eligible to participate in the program if you are a pharmacist at a regional Victorian hospital that is participating in the primary PRECISION-ITS trial.
The program will focus on pharmacogenomics service at participating sites in regional Victoria. The program will be evaluated by implementation science frameworks and participant end-user surveys.
It is hoped that this research will address pharmacists' education needs in pharmacogenomics and establish a framework for wider implementation to other healthcare professionals and craft groups.
It is hoped that this program will also facilitate pharmacogenomics knowledge translation into clinical practice, providing opportunities for rapid pharmacogenomics workforce capacity building, scalability and community acceptance beyond the trial.
Conditions
This trial is treating people with who have had cancer treatment themselves, cared for someone with cancer in Australia, are an oncology healthcare professional, or are a pharmacist at a participating site